Related Experiment Video
Updated: Dec 2, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Efficacy of hepatitis B vaccination in children with rheumatic diseases
Toaki Kohagura1, Shinji Kawabe1, Naoki Abe1
1Department of Infection and Immunology, Aichi Children's Health and Medical Center, Aichi, Japan.
Insights
Hepatitis B (HB) vaccination efficacy in children with rheumatic diseases is limited, especially with mycophenolate mofetil (MMF). Secondary vaccine series may be needed for these immunocompromised pediatric patients to achieve protection.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Vaccinology
Background:
- Hepatitis B (HB) vaccination is crucial for immunocompromised children.
- Limited data exists on HB vaccine efficacy in pediatric rheumatic disease patients on immunosuppressants.
Purpose of the Study:
- To evaluate the efficacy of HB vaccination in children with rheumatic diseases receiving immunosuppressive therapy.
- To identify factors affecting seroconversion rates after HB vaccination.
Main Methods:
- Retrospective analysis of pediatric patients with rheumatic diseases receiving HB vaccination during immunosuppressive treatment.
- Assessed seropositivity after primary and secondary vaccination series.
- Evaluated associations between specific immunosuppressants and seroconversion.
Main Results:
- 58% of patients achieved seropositivity after the primary HB vaccine series.
- Mycophenolate mofetil (MMF) was associated with significantly lower seroconversion rates (27%) compared to methotrexate (80%).
- A secondary vaccine series increased seropositivity to 86% in non-responders.
Conclusions:
- MMF significantly impedes seroconversion following primary HB vaccination in pediatric rheumatic disease patients.
- Secondary HB vaccination series are recommended for these patients to ensure adequate immune protection.
- Further research into optimal vaccination strategies for immunocompromised pediatric populations is warranted.
Background:
Vaccination to prevent hepatitis B (HB) virus infection is important for children undergoing immunosuppressive treatment. Information on the efficacy of HB vaccination in children with rheumatic diseases undergoing immunosuppressive therapy is scarce.
Methods:
Children with rheumatic diseases administered HB vaccine during immunosuppressive treatment between May 2013 and September 2016 were enrolled. Patients were vaccinated three times (primary series). Those who remained seronegative after the primary series received a secondary series of vaccinations. Patient baseline characteristics and treatment details from the medical records were retrospectively investigated. The proportion of patients that was seropositive for HB virus antibody after primary-and secondary series of vaccinations was calculated. Associations between immunosuppressants and serostatus were evaluated.
Results:
Fifteen of 26 patients (58%) produced anti-hepatitis B surface antibody (anti-HBs) after the primary vaccinations. Eight of 10 patients (80%) taking methotrexate and 3 of 11 (27%) taking mycophenolate mofetil (MMF) were seropositive. Multivariate analysis adjusted for dosage of prednisolone per body weight. Multivariate analysis showed MMF was a factor impeding seroconversion (odds ratio 0.093, 95% confidence interval 0.014-0.615). In six of seven patients (86%) who received a secondary series of vaccinations, anti-HBs were produced.
Conclusions:
MMF may impede seroconversion after a primary series of HB vaccinations, thus requiring secondary series of vaccinations in pediatric patients with a rheumatic disease undergoing immunosuppressive therapy.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Vaccinations
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test